Navigation Links
Life Technologies Sets 2nd Quarter 2011 Earnings Release Date for Thursday, July 28, 2011
Date:7/7/2011

CARLSBAD, Calif., July 7, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today it will report its second quarter 2011 financial results on Thursday, July 28, 2011, before market open. The company will also hold a webcast on the same day at 8:00 a.m. ET to discuss operating results, as well as future expectations.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

The webcast can be accessed through the investor relations page of the Life Technologies website at ir.lifetechnologies.com/events.cfm.  A replay of the webcast will be available on the Company's website through Thursday, August 18, 2011.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010,
'/>"/>

SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SYDNEY and SOUTHAMPTON , ... -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology ... into a research collaboration to develop a selective inhibitor to ... fatal lung disease idiopathic pulmonary fibrosis (IPF). ... US. Current products are expected to produce global revenues in ...
(Date:8/4/2015)... VIEW, Calif. , Aug. 4, 2015  IRIDEX ... James H. Mackaness , who had served as chief ... since 2012, has resigned his positions with the Company, ... officer position at another company. Mr. Mackaness intends to ... Company,s second quarter earnings announcement and 10-Q filing. ...
(Date:8/4/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... ended June 30, 2015 and provided a summary ... second quarter of 2015 and recent period marked ... Paul Grint, M.D., President and CEO of Regulus. ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10
... Reaffirms Primacy and Safety of ,First Generation, Antisense, ... (Nasdaq: GNTA ) announced the presentation of ... lead anticancer,compound, can be safely administered in high ... data were presented by Dr. Anthony Tolcher, Director,of ...
... - Studies Show Improvement in Hemodynamics and Delay ... Actelion Pharmaceuticals US, Inc.,today announced positive results from ... and effective as a combination therapy,for the treatment ... suggest that Tracleer, when given in combination with ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:8/5/2015)... , ... August 05, 2015 , ... ... have just published updated guidelines for the management of malignant pleural mesothelioma. Details ... to read the article. , The updated guidelines issued by the European ...
(Date:8/5/2015)... ... August 05, 2015 , ... Friendly Smiles Dental ... practice; Dr. Daniel H. Huynh, DMD and Dr. Michael J. Foley, DMD. The full ... patients at all three location in the Tampa Bay area, where Friendly Smiles Dental ...
(Date:8/5/2015)... ... ... Social Security benefits are not keeping pace with rising household budgets, according ... Citizens League (TSCL). The record low growth in cost-of-living adjustments (COLAs) in recent ... age 65 and older, says TSCL. , When asked to select between four statements ...
(Date:8/5/2015)... ... , ... Stelari introduces their new collection, The Earth’s Song, inspired by the ... Earth’s Song. Combining fashion and activewear, Stelari’s new collection let’s you take your bohemian ... this collection is sure to make the spirit seeker swoon with prints as meaningful ...
(Date:8/5/2015)... ... ... A leader in Primary Care Continuing Medical Education (CME), Continuing Education ... as its new Director of Program Management. , Su has over 16 years experience ... Primary Care Network (PCN) as the Director, Program Implementation as well as Supervisor of ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma 2Health News:Friendly Smiles Dental Care Welcomes New Doctors 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 3Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 3
... Cancer At All Stages Steps Away From Home, ... ... Medical University of,South Carolina (MUSC) Foundation for Research and Development announced ... for bladder cancer have shown to be accurate for only 40 ...
... of,National Problem Gambling Awareness Week, the state departments ... of counseling,and treatment services available to those affected ... not only the gambler but also their family,and ... Commonwealth,of Pennsylvania is committed to addressing compulsive gambling ...
... 10 Medco Health,Solutions, Inc. (NYSE: MHS ) ... follows:, On Monday, March 17, 2008, Timothy C. ... Inc., Medco,s specialty pharmacy,subsidiary, is scheduled to address the ... at the Boston Marriott Copley,Place will begin at 1:45 ...
... health insurance programs do not provide coverage to international ... ... Seven Corners, one of the,industry,s most experienced travel health insurance ... they,plan to travel abroad for spring break vacations. Most health insurance,programs ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
... ZARS Pharma, Inc. announced,today the completion of ... promotion and distribution rights for all markets ... (lidocaine and tetracaine) Cream,7%/7%, a topical anesthetic ... patients undergoing potentially painful cosmetic and other,skin ...
Cached Medicine News:Health News:Cell Receptor on Track for Painless Bladder Cancer Test 2Health News:State Agencies Highlight Available Assistance During Problem Gambling Awareness Week 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 3Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: